Daiichi Sankyo Company, Limited
GPTKB entity
Statements (88)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Ranbaxy_Laboratories
U. S. rights to Dronedarone (Multaq) for paroxysmal atrial fibrillation U. S. rights to Dronedarone (Multaq) for ventricular tachycardia U. S. rights to Dronedarone (Multaq) for persistent atrial fibrillation U. S. rights to Dronedarone (Multaq) for recurrent chronic atrial fibrillation U. S. rights to Azor U. S. rights to Benicar U. S. rights to Daxas U. S. rights to Dronedarone U. S. rights to Dronedarone (Multaq) U. S. rights to Edarbi U. S. rights to Tribenzor U. S. rights to Welchol U. S. rights to Dronedarone (Multaq) for recurrent atrial flutter U. S. rights to Dronedarone (Multaq) for atrial fibrillation U. S. rights to Dronedarone (Multaq) for heart failure U. S. rights to Dronedarone (Multaq) for chronic atrial fibrillation U. S. rights to Dronedarone (Multaq) for recurrent ventricular tachycardia U. S. rights to Dronedarone (Multaq) for recurrent atrial fibrillation U. S. rights to Dronedarone (Multaq) for recurrent persistent atrial fibrillation U. S. rights to Dronedarone (Multaq) for recurrent recurrent atrial fibrillation U. S. rights to Dronedarone (Multaq) for recurrent paroxysmal atrial fibrillation U. S. rights to Dronedarone (Multaq) for atrial flutter |
| gptkbp:ceo |
gptkb:Seigo_Kikuchi
gptkb:J._Scott_Mc_Culloch |
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:conducts_research_on |
gptkb:Dr._Masato_S._Kato
Dr. Masahiro Kuroda |
| gptkbp:employees |
approximately 15,000
|
| gptkbp:founded |
gptkb:2005
|
| gptkbp:founder |
gptkb:Daiichi_Pharmaceutical
|
| gptkbp:global_presence |
over 20 countries
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| gptkbp:healthcare |
generic drugs
biologics small molecules over-the-counter drugs specialty pharmaceuticals |
| https://www.w3.org/2000/01/rdf-schema#label |
Daiichi Sankyo Company, Limited
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:key_people |
gptkb:Yoshihiro_Kato
|
| gptkbp:market_cap |
$40 billion (2022)
$40 billion (2021) |
| gptkbp:number_of_employees |
around 15,000
|
| gptkbp:parent_company |
gptkb:Daiichi_Sankyo_Group
|
| gptkbp:partnership |
gptkb:GSK
gptkb:Johnson_&_Johnson gptkb:Takeda_Pharmaceutical_Company gptkb:Astra_Zeneca gptkb:Sanofi gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Santen_Pharmaceutical gptkb:Merck_&_Co. gptkb:Roche gptkb:Amgen gptkb:Eisai gptkb:Otsuka_Pharmaceutical gptkb:Chugai_Pharmaceutical gptkb:Astellas_Pharma gptkb:Abb_Vie gptkb:Novartis gptkb:Kyowa_Kirin gptkb:Daiichi_Sankyo_Healthcare |
| gptkbp:products |
antibiotics
vaccines oncology drugs |
| gptkbp:region |
global
|
| gptkbp:research_and_development |
focus on oncology
focus on infectious diseases focus on cardiovascular diseases |
| gptkbp:research_focus |
central nervous system disorders
cardiovascular diseases infectious diseases pain management metabolic diseases |
| gptkbp:revenue |
$10 billion (2020)
$10 billion (2022) |
| gptkbp:stock_symbol |
4568. T
|
| gptkbp:subsidiary |
gptkb:Daiichi_Sankyo_Europe_Gmb_H
gptkb:Daiichi_Sankyo,_Inc. |
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
www.daiichisankyo.com
|
| gptkbp:bfsParent |
gptkb:Daiichi_Sankyo_Europe_Gmb_H
gptkb:Daiichi_Sankyo,_Inc. |
| gptkbp:bfsLayer |
6
|